These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23977244)

  • 21. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
    Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reproductive Risk Factors Associated with Breast Cancer Molecular Subtypes among Young Women in Northern China.
    Wang JM; Wang J; Zhao HG; Liu TT; Wang FY
    Biomed Res Int; 2020; 2020():5931529. PubMed ID: 32337260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
    Lv M; Li B; Li Y; Mao X; Yao F; Jin F
    Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya.
    Sayed S; Fan S; Moloo Z; Wasike R; Bird P; Saleh M; Shaikh AJ; Figueroa JD; Naidoo R; Makokha FW; Gardner K; Oigara R; Njoroge FW; Magangane P; Mutebi M; Chauhan R; Mwanzi S; Govender D; Yang XR
    Breast Cancer Res; 2021 Jun; 23(1):68. PubMed ID: 34174935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
    Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
    Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers.
    Murase K; Yanai A; Saito M; Imamura M; Miyagawa Y; Takatsuka Y; Inoue N; Ito T; Hirota S; Sasa M; Katagiri T; Fujimoto Y; Hatada T; Ichii S; Nishizaki T; Tomita N; Miyoshi Y
    Breast Cancer; 2014 Jan; 21(1):52-7. PubMed ID: 22359195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of Basal-like and Luminal Breast Cancers among Black Women in the AMBER Consortium.
    Benefield HC; Zirpoli GR; Allott EH; Shan Y; Hurson AN; Omilian AR; Khoury T; Hong CC; Olshan AF; Bethea TN; Bandera EV; Palmer JR; Ambrosone CB; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2021 Jan; 30(1):71-79. PubMed ID: 33097496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathology of Senegalese breast cancers.
    Fitzpatrick MB; Rendi MH; Kiviat NB; Toure P; Dem A; Sow PS; Hawes SE; Feng Q; Allison KH
    Pan Afr Med J; 2019; 34():67. PubMed ID: 31819783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Reproductive Factors on the Risk of Breast Cancer by ER/PR and HER2: A Multicenter Case-Control Study in Northern and Eastern China.
    Xie F; Liu L; Yang H; Liu M; Wang S; Guo J; Yu L; Zhou F; Wang F; Xiang Y; Yu Z; Wang S
    Oncologist; 2022 Feb; 27(1):e1-e8. PubMed ID: 35305101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of ER, PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India.
    Singh R; Gupta S; Pawar SB; Pawar RS; Gandham SV; Prabhudesai S
    J Cancer Res Ther; 2014; 10(1):26-8. PubMed ID: 24762482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms.
    Grimm LJ; Zhang J; Mazurowski MA
    J Magn Reson Imaging; 2015 Oct; 42(4):902-7. PubMed ID: 25777181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
    Ritte R; Lukanova A; Berrino F; Dossus L; Tjønneland A; Olsen A; Overvad TF; Overvad K; Clavel-Chapelon F; Fournier A; Fagherazzi G; Rohrmann S; Teucher B; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Sieri S; Panico S; Tumino R; Vineis P; Quirós JR; Buckland G; Sánchez MJ; Amiano P; Chirlaque MD; Ardanaz E; Sund M; Lenner P; Bueno-de-Mesquita B; van Gils CH; Peeters PH; Krum-Hansen S; Gram IT; Lund E; Khaw KT; Wareham N; Allen NE; Key TJ; Romieu I; Rinaldi S; Siddiq A; Cox D; Riboli E; Kaaks R
    Breast Cancer Res; 2012 May; 14(3):R76. PubMed ID: 22583394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiological risk factors associated with inflammatory breast cancer subtypes.
    Atkinson RL; El-Zein R; Valero V; Lucci A; Bevers TB; Fouad T; Liao W; Ueno NT; Woodward WA; Brewster AM
    Cancer Causes Control; 2016 Mar; 27(3):359-66. PubMed ID: 26797453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions of hormone replacement therapy, body weight, and bilateral oophorectomy in breast cancer risk.
    Cui Y; Deming-Halverson SL; Beeghly-Fadiel A; Lipworth L; Shrubsole MJ; Fair AM; Shu XO; Zheng W
    Clin Cancer Res; 2014 Mar; 20(5):1169-78. PubMed ID: 24423614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
    Tas F
    Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.